AMGN - NASDAQ
Amgen Inc.
$338.22
+3.0%Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
At a Glance
Live SnapshotAmgen Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Amgen Inc. Income Statement
AMGN • NASDAQ
| Amgen Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
36.7B | 33.4B | 28.2B | 26.3B | 26B | 25.4B | 23.4B | 23.7B | 22.8B | 23B | 21.7B | 20.1B | 18.7B | 17.3B | 15.6B | 15.1B | 14.6B | 15B | 14.8B | 14.3B | |
GROSS PROFIT | ||||||||||||||||||||
(10.7B) | (12.9B) | (8.4B) | (6.4B) | (6.5B) | (6.2B) | (4.4B) | (4.1B) | (4.1B) | (4.2B) | (4.2B) | (4.4B) | (3.3B) | (2.9B) | (2.4B) | (2.2B) | (2.1B) | (2.3B) | (2.5B) | (2.1B) | |
26B | 20.6B | 19.8B | 19.9B | 19.5B | 19.3B | 19B | 19.6B | 18.8B | 18.8B | 17.4B | 15.6B | 15.3B | 14.3B | 13.2B | 12.8B | 12.6B | 12.7B | 12.2B | 12.2B | |
OPERATING INCOME | ||||||||||||||||||||
(15.3B) | (13.3B) | (11.8B) | (10.4B) | (11.9B) | (10.1B) | (9.3B) | (9.4B) | (8.8B) | (9B) | (9B) | (9.5B) | (9.5B) | (8.5B) | (8.6B) | (7.3B) | (7B) | (7.5B) | (8.2B) | (8.3B) | |
(7.1B) | (7.1B) | (6.2B) | (5.4B) | (5.4B) | (5.7B) | (5.2B) | (5.3B) | (4.9B) | (5.1B) | (4.8B) | (4.7B) | (5.2B) | (4.8B) | (4.5B) | (4B) | (3.8B) | (3.8B) | (3.4B) | (3.4B) | |
(7B) | (6B) | (4.8B) | (4.4B) | (6.3B) | (4.2B) | (4.1B) | (3.7B) | (3.6B) | (3.8B) | (4.1B) | (4.3B) | (4.1B) | (3.4B) | (3.2B) | (2.9B) | (2.9B) | (3B) | (3.3B) | (3.4B) | |
10.7B | 7.3B | 7.9B | 9.6B | 7.6B | 9.1B | 9.7B | 10.3B | 10B | 9.8B | 8.5B | 6.2B | 5.9B | 5.6B | 4.3B | 5.5B | 5.5B | 5.2B | 4B | 3.8B | |
PRE-TAX INCOME | ||||||||||||||||||||
(2.8B) | (3.2B) | (2.9B) | (1.4B) | (1.2B) | (1.3B) | (1.3B) | (1.4B) | (1.3B) | (1.3B) | (1.1B) | (1.1B) | (1B) | (1.1B) | (610M) | (604M) | (578M) | (551M) | (0.0) | (0.0) | |
-2.8B | -3.2B | -2.9B | -1.4B | -1.2B | -1.3B | -702M | -718M | -376M | -631M | -492M | -606M | -602M | -568M | -162M | -228M | -302M | -199M | 0.0 | 0.0 | |
(1.3B) | (248M) | (879M) | (503M) | (194M) | (189M) | (66M) | (314M) | (375M) | (133M) | (49M) | (454M) | (196M) | (295M) | (896M) | (411M) | (361M) | (674M) | (1.6B) | (1.6B) | |
-1.7B | -2.6B | -42M | -2.2B | -938M | -1B | -536M | -718M | -376M | -631M | -492M | -606M | -602M | -568M | -162M | -228M | -302M | -199M | -19M | 180M | |
9B | 4.6B | 7.9B | 7.3B | 6.7B | 8.1B | 9.1B | 9.5B | 9.6B | 9.2B | 8B | 5.6B | 5.3B | 5B | 4.2B | 5.3B | 5.2B | 5.3B | 4B | 4B | |
NET INCOME | ||||||||||||||||||||
(1.3B) | (519M) | (1.1B) | (794M) | (808M) | (869M) | (1.3B) | (1.2B) | (7.6B) | (1.4B) | (1B) | (427M) | (184M) | (664M) | (467M) | (690M) | (599M) | (1.1B) | (795M) | (1.1B) | |
7.7B | 4.1B | 6.7B | 6.6B | 5.9B | 7.3B | 7.8B | 8.4B | 2B | 7.7B | 6.9B | 5.2B | 5.1B | 4.3B | 3.7B | 4.6B | 4.6B | 4.2B | 3.2B | 3B |
SEC Filings
AMGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 |
Related Guides
Continue your AMGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.